SUTRO BIOPHARMA ($STRO) posted quarterly earnings results on Thursday, August 7th. The company reported earnings of -$0.14 per share, beating estimates of -$0.41 by $0.27. The company also reported revenue of $63,750,000, beating estimates of $14,537,856 by $49,212,144.
You can see Quiver Quantitative's $STRO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SUTRO BIOPHARMA Hedge Fund Activity
We have seen 60 institutional investors add shares of SUTRO BIOPHARMA stock to their portfolio, and 62 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 4,434,637 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,885,174
- CITADEL ADVISORS LLC removed 2,317,428 shares (-94.3%) from their portfolio in Q1 2025, for an estimated $1,507,718
- POINT72 ASSET MANAGEMENT, L.P. removed 2,197,538 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,429,718
- MPM BIOIMPACT LLC removed 2,160,062 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,405,336
- KYNAM CAPITAL MANAGEMENT, LP added 1,800,000 shares (+49.4%) to their portfolio in Q1 2025, for an estimated $1,171,080
- PARKMAN HEALTHCARE PARTNERS LLC removed 1,727,925 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,124,188
- EVERSEPT PARTNERS, LP added 1,597,853 shares (+230.1%) to their portfolio in Q1 2025, for an estimated $1,039,563
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SUTRO BIOPHARMA Analyst Ratings
Wall Street analysts have issued reports on $STRO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 06/16/2025
- B of A Securities issued a "Underperform" rating on 05/19/2025
To track analyst ratings and price targets for SUTRO BIOPHARMA, check out Quiver Quantitative's $STRO forecast page.
SUTRO BIOPHARMA Price Targets
Multiple analysts have issued price targets for $STRO recently. We have seen 5 analysts offer price targets for $STRO in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Edward Tenthoff from Piper Sandler set a target price of $2.0 on 06/16/2025
- Tazeen Ahmad from B of A Securities set a target price of $0.8 on 05/19/2025
- Andres Maldonado from HC Wainwright & Co. set a target price of $2.0 on 04/29/2025
- David Nierengarten from Wedbush set a target price of $2.0 on 03/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
